PRJNA576908
p62/Sequestome1(SQSTM-1)-engineered Lactobacilli as biotherapeutic agents in Alzheimer's disease
p62/Sequestome1/(SQSTM-1)-engineered Lactobacilli, in details L. lactis MG1363, were orally administered to transgenic Alzheimer's disease mice, namely 3xTg-AD. Upon four months treatment, effects on AD major hallmarks such as cognitive deficits, amyloid deposition, proteolysis dysfunctions, oxidation and inflammation were dissected. The ability to modulate microbiota composition was also evaluated.